David Liu-founded startup Prime Medicine makes Nasdaq debut


Prime Medicine Inc., the gene-editing startup co-founded by the scientist behind Editas Medicine Inc. and Beam Therapeutics, has gone public in a $175 million IPO.

Previous Viewpoint: Families of color spurn stock investments to their detriment
Next Greystone Hall mansion and 44-acre property in Chester County listed for $9M